LPTX
Cypherpunk Technologies Inc.2.0500
+1.6125+369%
Nov 12, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
116.14MP/E (TTM)
-Basic EPS (TTM)
-1.58Dividend Yield
0%Recent Filings
8-K
Nasdaq bid price warning
Cypherpunk Technologies received a Nasdaq deficiency notice on March 4, 2026, for its common stock's closing bid price lingering below $1.00 over 30 business days, violating Rule 5550(a)(2). It has 180 days until August 31 to hit $1.00 for 10 straight days. Trading continues uninterrupted. No delisting yet, but reverse split looms if needed.
8-K
Buys more ZEC, hits 1.76%
Cypherpunk Technologies bought an additional 56,418.09 ZEC for ~$29 million at $514.02 average, boosting total holdings to 290,062.67 ZEC—1.76% of circulating supply—at a cumulative $334.41 per ZEC. This accelerates their treasury strategy toward 5% ownership. ZEC price volatility correlates with stock risk.
8-K
Reissued 5.4M RSUs to CoinXit
Cypherpunk Technologies canceled 2,411,700 prior RSUs to consultant CoinXit and reissued 5,448,157 RSUs under its 2025 Plan on December 23, 2025, fully satisfying consulting obligations tied to Winklevoss investor ties. RSUs vest 12/36ths on October 8, 2026, then monthly, with full acceleration on non-Cause termination sans ongoing service. Ties up loose ends cleanly.
8-K
Approves equity plan, share increase
Cypherpunk Technologies stockholders approved the 2025 Equity Incentive Plan with 31,454,785 shares and doubled authorized common stock to 490M shares at the December 15, 2025 special meeting. Charter amendment filed same day. Nasdaq confirmed compliance with minimum bid price rule on December 11. Stockholders aligned.
8-K
Waiver frees warrant shares
Cypherpunk Technologies signed a waiver with Winklevoss Capital on November 19, 2025, freeing 57,182,378 warrant shares for its $200 million at-the-market equity program. Winklevoss can't exercise those until authorized shares hit 490 million or a 1:5 reverse split occurs. This unlocks capital access. Remaining warrant shares stay unaffected.
AKTX
Akari Therapeutics Plc
0.25-0.16
APRE
Aprea Therapeutics, Inc.
0.91-0.01
APTOF
Aptose Biosciences. Inc.
1.60-0.04
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
KAPA
Kairos Pharma, Ltd.
0.74+0.00
KPTI
Karyopharm Therapeutics Inc.
6.33-0.38
LIXT
Lixte Biotechnology Holdings, I
4.10+0.11
MNPR
Monopar Therapeutics Inc.
71.47-3.65
RAPT
RAPT Therapeutics, Inc.
34.03+0.81
RPTX
Repare Therapeutics Inc.
2.23+0.03